Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event

Reuters

Yesterday

<a href="https://laohu8.com/S/FLGT">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event

Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, "We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025." Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2532386458"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532386458\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532386458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-03 09:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532386458","market":"us","top_or_hot":-1,"title":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-03 09:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics Inc.</a> Releases Transcript for Q1 2025 Earnings Call Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250503:nNDLbwkDF9:1","article_id":"2532386458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532386458","pubTimestamp":1746234431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"Fulgent Genetics Inc.发布2025年第一季度收益看涨期权活动记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"Fulgent Genetics Inc. Releases Transcript for Q1 2025 Earnings Call Event\n    \n\n        Fulgent Genetics Inc. recently published the transcript of their Q1 2025 earnings call, held on May 2, 2025. The event was attended by key company figures, including CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, with Melanie Solomon from Investor Relations facilitating the call. During the call, the management highlighted the company's strong performance in the first quarter of 2025, showcasing year-over-year growth in their Laboratory Services. CEO Ming Hsieh expressed optimism, stating, \"We are pleased with our first-quarter results, having shown year-over-year growth in Laboratory Services, and we are seeing great, good momentum in 2025.\" Additionally, the company discussed the progress of their Therapeutic Development pipeline, emphasizing that their first clinical candidate, FID-007, is on track with its Phase 2 clinical trial. The full transcript can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief on May 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}